Samaritan's European patent for SP-1000 for cardiovascular disease allowed

By Lisa Kerner

Charlotte, N.C., June 20 - Samaritan Pharmaceuticals Inc. said it has received a notice of allowance of claims for its European patent application, which relates to Samaritan's drug SP-1000 for the treatment of cardiovascular disease.

The patent will be awarded to Georgetown University and is exclusively licensed to Samaritan, according to a company news release.

In two preclinical animal studies, SP-1000 was found to reduce blood cholesterol, clear clogged arteries of atheroma; raise HDL (the good cholesterol) and reduce CK enzyme elevation, a marker for heart suffering.

Located in Las Vegas, Samaritan discovers, develops and commercializes therapeutics for AIDS, Alzheimer's disease, cancer and heart disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.